Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective

被引:69
作者
Lindgren, Peter
Lindstrom, Jaana
Tuomilehto, Jaakko
Uusitupa, Matti
Peltonen, Markku
Jonsson, Bengt
de Faire, Ulf
Hellenius, Mal-Lis
机构
[1] Karolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, SE-17177 Stockholm, Sweden
[2] European Hlth Econ, SE-11120 Stockholm, Sweden
[3] Natl Publ Hlth Inst, Dept Hlth Promot & Chron Dis Prevent, SF-00300 Helsinki, Finland
[4] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland
[5] Univ Kuopio, Sch Publ Hlth & Clin Nutr, Dept Clin Nutr, FIN-70211 Kuopio, Finland
[6] Natl Publ Hlth Inst, Diabet Unit, Helsinki 00300, Finland
[7] Stockholm Sch Econ, Ctr Hlth Econ, SE-11383 Stockholm, Sweden
[8] Karolinska Hosp, Cardiovasc Lab, SE-17176 Stockholm, Sweden
[9] Karolinska Inst, Dept Neurobiol, S-14183 Huddinge, Sweden
[10] Stockholm Cty Council, Ctr Family & Community Med, S-14183 Huddinge, Sweden
关键词
diabetes mellitus type 2; primary prevention; lifestyle; glucose intolerance; economics;
D O I
10.1017/S0266462307070286
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: The Finnish Diabetes Prevention Study (DPS) was a randomized intervention program that evaluated the effect of intensive lifestyle modification on the development of diabetes mellitus type 2 in patients with impaired glucose tolerance. As such, a program is demanding in terms of resources; it is necessary to assess whether it would be money well spent. This determination was the purpose of this study. Methods: We developed a simulation model to assess the economic consequences of an intervention like the one studied in DPS in a Swedish setting. The model used data from the trial itself to assess the effect of intervention on the risk of diabetes and on risk factors for cardiovascular disease. Results from the United Kingdom Prospective Diabetes Study were used to estimate the risk of cardiovascular disease and stroke. Cost data were derived from Swedish studies. The intervention was assumed to be applied to eligible patients from a population-based screening program of 60-year-olds in the County of Stockholm from which the baseline characteristics of the patients was used. Results: The model predicted that implementing the program would be cost-saving from the healthcare payers' perspective. Furthermore, it was associated with an increase in estimated survival of .18 years. Taking into consideration the increased consumption by patients due to their longer survival, the predicted cost-effectiveness ratio was 2,363EURO per quality-adjusted life-year gained. Conclusions: Lifestyle intervention directed toward high-risk subjects would be cost-saving for the healthcare payer and highly cost-effective for society as a whole.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 32 条
[1]  
Barnard R J, 2002, Obes Rev, V3, P303, DOI 10.1046/j.1467-789X.2002.00081.x
[2]  
Bonow Robert O., 2004, American Journal of Medicine, V116, p2S
[3]   Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria [J].
Borch-Johnsen, K ;
Neil, A ;
Balkau, B ;
Larsen, S ;
Nissinen, A ;
Pekkanen, J ;
Tuomilehto, J ;
Jousilahti, P ;
Lindstrom, J ;
Pyörälä, M ;
Pyörälä, K ;
Eschwege, E ;
Gallus, G ;
Garancini, MP ;
Bouter, LM ;
Dekker, JM ;
Heine, RJ ;
Nijpels, HG ;
Stehouwer, CDA ;
Feskens, EJM ;
Kromhout, D ;
Peltonen, M ;
Pajak, A ;
Eriksson, J ;
Qiao, Q .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :397-405
[4]   MUST DIABETES BE A FATAL DISEASE IN AFRICA - STUDY OF COSTS OF TREATMENT [J].
CHALE, SS ;
SWAI, ABM ;
MUJINJA, PGM ;
MCLARTY, DG .
BRITISH MEDICAL JOURNAL, 1992, 304 (6836) :1215-1218
[5]   Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) [J].
Clarke, P ;
Gray, A ;
Holman, R .
MEDICAL DECISION MAKING, 2002, 22 (04) :340-349
[6]  
Colangelo LA, 2002, CANCER EPIDEM BIOMAR, V11, P385
[7]  
*CTR EP, 1999, SWED HOSP NAT DISCH
[8]  
*CTR EP, 2001, CAUS DEATH REG
[9]  
Diabet Prevention Program Res Grp, 2003, DIABETES CARE, V26, P2518, DOI 10.2337/diacare.26.9.2518
[10]  
EKMAN M, 2001, CONSUMPTION PRODUCTI